Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acne, Adult Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of Clear Skin Formula on Mitigating Mild to Moderate Non-cystic Acne

NCT05879406
View directory record Official record
Conditions
Non-Cystic Acne
Interventions
VitaMedica® Clear Skin Formula capsules, Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
18 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne

NCT03450369
View directory record Official record
Conditions
Acne Vulgaris
Interventions
NB01
Biological
Lead sponsor
Naked Biome, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne

NCT03709654
View directory record Official record
Conditions
Acne Vulgaris
Interventions
NB01, Vehicle Control
Biological · Other
Lead sponsor
Naked Biome, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
San Diego, California • Arlington, Texas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 22, 2026, 10:10 AM EDT
Terminated Early Phase 1 Interventional

Six Months Evaluation of Next Science Acne Creams on Facial Acne in Adult Females.

NCT03106766
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Acne cream 2X, Acne cream 1X
Drug
Lead sponsor
Next Science TM
Industry
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Jul 22, 2026, 10:10 AM EDT
Active, not recruiting Phase 2 Interventional

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

NCT06993610
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Tibulizumab Dose A, Tibulizumab Dose B, Placebo
Biological · Other
Lead sponsor
Zura Bio Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 10:10 AM EDT
Recruiting Early Phase 1 Interventional

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

NCT06645821
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
EVO101
Drug
Lead sponsor
Virginia Clinical Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Not applicable Interventional

"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"

NCT01082523
View directory record Official record
Conditions
Acne, Patient Compliance
Interventions
Text message reminders
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03713632
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
15
States / cities
San Diego, California • Whittier, California • Coral Gables, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 22, 2026, 10:10 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

NCT03713619
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Birmingham, Alabama • Rogers, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Not applicable Interventional

Evaluation of the Safety and Efficacy of an Acne Treatment Device

NCT06420804
View directory record Official record
Conditions
Mild to Moderate Acne
Interventions
ZIIP Acne Treatment Device
Device
Lead sponsor
ZIIP Beauty
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pleasant Hill, California
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RCT of an Oral Acne Supplement for Adult Women

NCT06097871
View directory record Official record
Conditions
Acne
Interventions
Skin Nutraceutical Supplement, Placebo pill
Dietary Supplement · Other
Lead sponsor
Nutraceutical Wellness Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Jul 22, 2026, 10:10 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

NCT02575950
View directory record Official record
Conditions
Acne Vulgaris
Interventions
LEO43204, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lomita, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jul 22, 2026, 10:10 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

NCT07207369
View directory record Official record
Conditions
Acne Scars
Interventions
ELAPR002f Injectable Gel, Saline Control
Device
Lead sponsor
AbbVie
Industry
Eligibility
22 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Glendale, Arizona • Redondo Beach, California • Vista, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

NCT05080764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

NCT04092452
View directory record Official record
Conditions
Acne Inversa
Interventions
PF-06650833, PF-06700841, PF-06826647, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
63
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 22, 2026, 10:10 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study To Investigate If Embody's Retinol Gummies Improve The Early Signs Of Skin Aging And Overall Skin Health

NCT04884516
View directory record Official record
Conditions
Acne, Adult
Interventions
Retinol gummy
Dietary Supplement
Lead sponsor
Embody Beauty, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Jul 22, 2026, 10:10 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Ocular Screening in Children and Young Adults at Risk for Increased Intracranial Pressure

NCT03286426
View directory record Official record
Conditions
Intracranial Pressure Increase
Interventions
Pictor
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Phase 2 Interventional

DMT210 Topical Gel in the Treatment of Acne Rosacea

NCT03003104
View directory record Official record
Conditions
Acne Rosacea
Interventions
DMT210 Topical Gel 5%, Vehicle Control
Drug · Other
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
San Diego, California • Miami, Florida • Fridley, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Evaluating the Efficacy and Safety of TheraClearX on Mitigating Mild to Moderate Acne

NCT06043102
View directory record Official record
Conditions
Acne
Interventions
TheraClearX
Device
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
12 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 22, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Evaluating the Efficacy and Safety of Omnilux Clear on Mitigating Mild to Moderate Acne

NCT06936332
View directory record Official record
Conditions
Acne
Interventions
Omnilux Clear Light Emitting Diode Treatment
Device
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Jul 22, 2026, 10:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

NCT06316297
View directory record Official record
Conditions
Acne
Interventions
Acne mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
79
States / cities
Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 10:10 AM EDT